TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12717237

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG) 1.5 mg/kg during the anhepatic phase followed by 1.5 mg/kg on posttransplant day 1
Number of subjects: 119

Group type: COMPARATOR
Intervention: Methylprednisolone 1,000 mg followed by a 3-month steroid taper
Number of subjects: 119
Study: 10657415

Group type: EXPERIMENTAL
Intervention: Estrogen for secondary stroke prevention
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Diabetes-adjusted guidelines (<130/85 mm Hg for diabetics, <140/90 mm Hg for nondiabetics)
Number of subjects: 644
Study: 9404752

Group type: EXPERIMENTAL
Intervention: Residual Volume (RV) method
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Functional Residual Capacity (FRC) method
Number of subjects: 12
Study: 8304789

Group type: EXPERIMENTAL
Intervention: 2.5 g dipyrone combined with a spasmolytic agent and 30 mg ketorolac tromethamine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 34
Study: 2878600

Group type: EXPERIMENTAL
Intervention: Bevantolol 150 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 40
Study: 29210007

Group type: EXPERIMENTAL
Intervention: Bilateral varicocelectomy (n=179)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Unilateral varicocelectomy (n=179)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Bilateral varicocelectomy
Number of subjects: 358

Group type: COMPARATOR
Intervention: Unilateral varicocelectomy
Number of subjects: 358
Study: 28139557

Group type: EXPERIMENTAL
Intervention: Trimetazidine 35 mg twice daily
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg twice daily
Number of subjects: 107

Group type: COMPARATOR
Intervention: Combination of bisoprolol 1.25‐2.5 mg once daily and ivabradine 2.5‐7.5 mg twice daily
Number of subjects: 107
Study: 25762833

Group type: EXPERIMENTAL
Intervention: Synthetic glue (group A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Subcuticular sutures (group B)
Number of subjects: 89
Study: 22212127

Group type: EXPERIMENTAL
Intervention: Tdap vaccine (Boostrix(®))
Number of subjects: 1104
Study: 20159247

Group type: EXPERIMENTAL
Intervention: Intravenous montelukast 7 mg
Number of subjects: 583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study: 17627746

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 16278987

Group type: EXPERIMENTAL
Intervention: Phenylalanine-free essential amino acid tablets (AA tablets)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 19
Study: 12385350

Group type: EXPERIMENTAL
Intervention: Medicated ribbon gauze
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ear wick
Number of subjects: 94
Study: 9951432

Group type: EXPERIMENTAL
Intervention: Combination of 7.5 mg hydrocodone bitartrate with 200 mg ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7790461

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 23

Group type: COMPARATOR
Intervention: bismuth, metronidazole, and nitrofurantoin
Number of subjects: 23

Group type: COMPARATOR
Intervention: bismuth-antibiotic
Number of subjects: 23
Study: 2133751

Group type: EXPERIMENTAL
Intervention: S26 Low Birthweight
Number of subjects: 49

Group type: COMPARATOR
Intervention: Enfalac Premature
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both preterm infant formulas
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Preterm breast milk supplemented with preterm infant formula
Number of subjects: 49
Study: 30607985

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation therapy (VRT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Vestibular rehabilitation therapy (VRT) plus placebo
Number of subjects: 2
Study: 28049549

Group type: EXPERIMENTAL
Intervention: 'Get Fit for Active Living (GFAL)' program
Number of subjects: 176
Study: 26576520

Group type: EXPERIMENTAL
Intervention: High flow group
Number of subjects: 130

Group type: COMPARATOR
Intervention: Low flow group
Number of subjects: 130
Study: 23425194

Group type: EXPERIMENTAL
Intervention: Medium-hard toothbrushes
Number of subjects: 35

Group type: COMPARATOR
Intervention: Soft toothbrushes
Number of subjects: 35
Study: 21499862

Group type: EXPERIMENTAL
Intervention: gemcitabine
Number of subjects: 451

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 451
Study: 19357317

Group type: EXPERIMENTAL
Intervention: Imidacloprid-treated seedlings (Merit Forest)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cypermethrin-treated seedlings (Forester)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Untreated seedlings
Number of subjects: 19
Study: 16368345

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15086356

Group type: EXPERIMENTAL
Intervention: Folic acid plus vitamin B(6) (5 mg of folic acid plus 250 mg of vitamin B(6) daily)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 158
Study: 11228214

Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 0
Study: 9196141

Group type: EXPERIMENTAL
Intervention: 20 Gy EF irradiation
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 30 Gy EF irradiation
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 40 Gy EF irradiation
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 40 Gy for bulky disease
Number of subjects: 257
Study: 8389710

Group type: EXPERIMENTAL
Intervention: T3 therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3318711

Group type: EXPERIMENTAL
Intervention: Penicillamine 20 mg/kg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Penicillamine plus prednisolone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 15
Study: 30558143

Group type: EXPERIMENTAL
Intervention: Amino Acids (BCAA, Arginine, Citrulline)
Number of subjects: 16
Study: 26286756

Group type: EXPERIMENTAL
Intervention: Clear IOLs (AcrySof UV‐filtering IOL, SA60AT)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Yellow IOLs (AcrySof Natural blue‐light‐attenuating and UV‐filtering IOL, SN60AT with IMPRUV(®) filter)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Orange‐tinted blue‐filtering IOLs (PC440Y Optech)
Number of subjects: 98
Study: 24457184

Group type: EXPERIMENTAL
Intervention: eGFR (CKD‐EPI‐Creat+CysC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: eGFR (MDRD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eGFR (CKD‐EPI‐Creat+CysC) and eGFR (MDRD)
Number of subjects: 0
Study: 24350695

Group type: EXPERIMENTAL
Intervention: Nonlinear frequency compression (NLFC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional processing
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NLFC
Number of subjects: 44
Study: 20033904

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (EET) for 12 months, 3 hours a week
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 17923439

Group type: EXPERIMENTAL
Intervention: 10-week karate program
Number of subjects: 11
Study: 16357522

Group type: EXPERIMENTAL
Intervention: EGF vaccine (single or double dose, weekly for four weeks and monthly thereafter)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: EGF vaccine (double dose)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: EGF vaccine (good antibody response)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: EGF vaccine (serum EGF decreased below 168 pg/ml)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: EGF vaccine (overall treatment)
Number of subjects: 43
Study: 15273838

Group type: EXPERIMENTAL
Intervention: Dexamethasone administered before antibiotic therapy (Group I - 25 patients)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dexamethasone administered concomitantly with antibiotics (Group II - 19 patients)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dexamethasone administered after beginning antibiotic therapy (Group III - 14 patients)
Number of subjects: 81

Group type: COMPARATOR
Intervention: No dexamethasone (Group IV - 23 patients)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Overall analysis of neurological alterations
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Hearing loss
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Psychological evaluation using WPSSI and WISC tests
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Overall analysis of sequelae (neurological, auditory, and intellectual level)
Number of subjects: 81
Study: 11743380

Group type: EXPERIMENTAL
Intervention: Collagen/elastin substitute combined with autograft
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional split-thickness autograft
Number of subjects: 86
Study: 9024949

Group type: EXPERIMENTAL
Intervention: Intrathecal TRH
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intravenous TRH
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intrathecal TRH (readministered)
Number of subjects: 2
Study: 8510087

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg and Hydrochlorothiazide 25 mg daily for 16 weeks
Number of subjects: 139

Group type: COMPARATOR
Intervention: Captopril or Hydrochlorothiazide monotherapy for 4 weeks
Number of subjects: 139
Study: 2879981

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb strain by subcutaneous injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Schwarz strain by subcutaneous injection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb strain by aerosol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Schwarz strain by aerosol
Number of subjects: 100
Study: 31302339

Group type: COMPARATOR
Intervention: SPX-101 (20 to 240 mg single doses and 10 to 120 mg BID for 14 days)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: SPX-101 (10 mg-120 mg BID for 7 days)
Number of subjects: 69
Study: 26988864

Group type: EXPERIMENTAL
Intervention: SRP + 1.2% ATV gel
Number of subjects: 71

Group type: COMPARATOR
Intervention: SRP + placebo gel
Number of subjects: 71
Study: 25610954

Group type: EXPERIMENTAL
Intervention: 500 mL of chocolate milk daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 0
Study: 23419544

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 21170659

Group type: EXPERIMENTAL
Intervention: Emergency SEMS placement as a bridge to surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Emergency surgery
Number of subjects: 60
Study: 19843656

Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg BID for 10 days followed by 10 mg BID for 6 days
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Asenapine 15 mg BID for 10 days followed by 20 mg BID for 6 days
Number of subjects: 148

Group type: COMPARATOR
Intervention: Quetiapine 375 mg BID for 16 days
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo for 16 days
Number of subjects: 148
Study: 17074351

Group type: EXPERIMENTAL
Intervention: Oral estrogen supplementation
Number of subjects: 0
Study: 14764210

Group type: EXPERIMENTAL
Intervention: Isobaric rectal distension
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham distension
Number of subjects: 12
Study: 11506110

Group type: EXPERIMENTAL
Intervention: Automatic tube compensation during APRV
Number of subjects: 14

Group type: COMPARATOR
Intervention: APRV without automatic tube compensation
Number of subjects: 14
Study: 9491583

Group type: EXPERIMENTAL
Intervention: Monetary task incentive framed in terms of gains (promotion framed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monetary task incentive framed in terms of losses (prevention framed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promotion-framed task incentives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prevention-framed task incentives
Number of subjects: 0
Study: 8737557

Group type: EXPERIMENTAL
Intervention: Early trabeculectomy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Medical therapy with topical beta blockers
Number of subjects: 70
Study: 3595257

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (M) mixed with poly(I).poly(C) (90 mg/m2)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Free Mitoxantrone (M) (30 mg/m2)
Number of subjects: 5
Study: 29936289

Group type: EXPERIMENTAL
Intervention: Alarmist video
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: RF-ON trial
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: RF-OFF trial
Number of subjects: 44
Study: 27809792

Group type: EXPERIMENTAL
Intervention: FRIDs withdrawal
Number of subjects: 612

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 612
Study: 25068178

Group type: EXPERIMENTAL
Intervention: Cultural adaptation of a social cognitive theory‐based HIV behavioral prevention program
Number of subjects: 0
Study: 22717330

Group type: EXPERIMENTAL
Intervention: rHA 45 μg with Advax™ adjuvant
Number of subjects: 281

Group type: COMPARATOR
Intervention: rHA alone
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: rHA 3, 11 or 45 μg with or without adjuvant
Number of subjects: 281
Study: 19535612

Group type: EXPERIMENTAL
Intervention: Friendship-based HIV/STI prevention intervention
Number of subjects: 264
Study: 18795960

Group type: EXPERIMENTAL
Intervention: TMC125 (etravirine) 800 mg bid
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control PI
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: TMC125
Number of subjects: 116
Study: 15657693

Group type: EXPERIMENTAL
Intervention: Topical steroids (prednisolone acetate 1% eye drops 5x/day for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combined systemic (fluocortolone 1 mg/kg body weight per day tapered within 3 weeks) and topical steroids
Number of subjects: 40
Study: 12629101

Group type: EXPERIMENTAL
Intervention: 100 mg T enanthate, im, weekly plus 125 micro g LNG, orally, daily (T+LNG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Testosterone alone (T)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Levonorgestrel alone (LNG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo T plus placebo LNG (placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of T+LNG
Number of subjects: 100
Study: 11279969

Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine 4%
Number of subjects: 131

Group type: COMPARATOR
Intervention: Saline placebo 0.5 mL
Number of subjects: 131
Study: 9057446

Group type: EXPERIMENTAL
Intervention: Recurrent malaria patients with more than five attacks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Recurrent malaria patients
Number of subjects: 61

Group type: COMPARATOR
Intervention: Fresh and recurrent malaria patients
Number of subjects: 61
Study: 1907362

Group type: EXPERIMENTAL
Intervention: Morphine sulphate (0.12 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G: 0.03 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G: 0.06 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6351658

Group type: COMPARATOR
Intervention: Group A (prednisone and vincristine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group B (prednisone, vincristine, and L-asparaginase)
Number of subjects: 30
Study: 31350296

Group type: EXPERIMENTAL
Intervention: Very early and more frequent mobilization in addition to usual care
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 56
Study: 29587703

Group type: EXPERIMENTAL
Intervention: Structured exercise (STRUC)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Free/unstructured gym use (FREE)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Measurement only comparator (CONT)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Traditional supervised exercise (STRUC)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Combined (COMB)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Physical activity counselling (PAC)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Wait-list comparator (CONT)
Number of subjects: 480
Study: 27243774

Group type: EXPERIMENTAL
Intervention: 3HP
Number of subjects: 399

Group type: COMPARATOR
Intervention: 9H
Number of subjects: 399
Study: 24485633

Group type: EXPERIMENTAL
Intervention: High-dose furosemide (HDF, n=50, 20mg/h)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Low-dose furosemide and low-dose dopamine (LDFD, n=56, 5mg/h and 5 μg kg(‐1)min(‐1))
Number of subjects: 161

Group type: COMPARATOR
Intervention: Low-dose furosemide (LDF, n=55, 5mg/h)
Number of subjects: 161
Study: 22143923

Group type: EXPERIMENTAL
Intervention: Warm saline (42°C, 107°F)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Room-temperature saline
Number of subjects: 462
Study: 20426780

Group type: EXPERIMENTAL
Intervention: MAL PDT with visible light and water-filtered infrared A (VIS+wIRA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: MAL PDT with light from light-emitting diodes (LEDs)
Number of subjects: 80
Study: 18034900

Group type: EXPERIMENTAL
Intervention: Telephone interviews (CATI)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Self-administered questionnaires
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Order of administration (telephone interview first)
Number of subjects: 823
Study: 16136843

Group type: EXPERIMENTAL
Intervention: Caregiver training program (N = 24) consisting of four sessions, including watching investigators administer the Texas Functional Living Scale and cueing patients to perform tasks.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waiting list control group (N = 23)
Number of subjects: 47
Study: 12586806

Group type: EXPERIMENTAL
Intervention: 10 mg atrasentan
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 10509757

Group type: EXPERIMENTAL
Intervention: 300 g of cooked Brussels sprouts per day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucosinolate-free diet
Number of subjects: 10
Study: 7860905

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of amlodipine and atenolol
Number of subjects: 100
Study: 1753042

Group type: EXPERIMENTAL
Intervention: Postural hypotension assessment at 1 minute after standing
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Postural hypotension assessment at 3 minutes after standing
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Postural hypotension assessment at both time intervals (1 and 3 minutes)
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Postural hypotension assessment at either or both time intervals
Number of subjects: 4736
Study: 7020438

Group type: EXPERIMENTAL
Intervention: Specialized hypnotherapy (six brief sessions)
Number of subjects: 0
Study: 30853020

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 27932571

Group type: EXPERIMENTAL
Intervention: Esmolol, 1 mg/kg before aortic cross‐clamping and 2 mg/kg with Custodiol® crystalloid cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (equivolume)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26086920

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: 1 mg IVTA
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: 4 mg IVTA
Number of subjects: 682
Study: 24798072

Group type: EXPERIMENTAL
Intervention: eSET plus single-embryo cryotransfer
Number of subjects: 194

Group type: COMPARATOR
Intervention: Double embryo transfer (DET)
Number of subjects: 194
Study: 22952293

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette‐Guérin therapy
Number of subjects: 835
Study: 19571639

Group type: EXPERIMENTAL
Intervention: Restless legs syndrome patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 36
Study: 17293637

Group type: EXPERIMENTAL
Intervention: Low polyphenolic content beverage (LPC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High polyphenolic content beverage (HPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between LPC and HPC
Number of subjects: 20
Study: 15125467

Group type: EXPERIMENTAL
Intervention: GLP-2 (0.5 pmol kg body wt(‐1) min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-2 (1.0 pmol kg body wt(‐1) min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 (0.5 pmol kg body wt(‐1) min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 and GLP-2 (0.5 pmol kg body wt(‐1) min(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 16978305

Group type: EXPERIMENTAL
Intervention: Fentanyl (50 microg) with levobupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg) with levobupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levobupivacaine (0.25%) plus saline (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anaesthesia without paravertebral analgesia (control group)
Number of subjects: 0
Study: 10392863

Group type: EXPERIMENTAL
Intervention: Directional atherectomy (CMS system)
Number of subjects: 986

Group type: COMPARATOR
Intervention: Balloon angioplasty (CMS system)
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Directional atherectomy (ARTREK system)
Number of subjects: 986

Group type: COMPARATOR
Intervention: Balloon angioplasty (ARTREK system)
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: CMS system
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: ARTREK system
Number of subjects: 986
Study: 8895262

Group type: EXPERIMENTAL
Intervention: Dexamethasone 150 micrograms/kg up to a maximum dose of 8 mg, administered IV before surgery
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133